INSM1 is a sequence-specific DNA-binding transcriptional repressor essential for neuroendocrine differentiation and neurogenesis 1. It binds to consensus sequences in target promoters and recruits chr20-modifying complexes including HDAC1, HDAC2, HDAC3, KDM1A, and RCOR1 to suppress transcription 2. INSM1 plays critical roles in multiple developmental processes: promoting neural progenitor cell generation in the developing neocortex, directing differentiation of pancreatic, pituitary, and intestinal endocrine cells, and specifying sympatho-adrenal cell fate 3. It functions as a lineage-determining factor, with ASCL1-driven neuroendocrine tumors critically dependent on INSM1 expression alongside NKX2-1 and FOXA2 3. INSM1 also inhibits cell proliferation through cell cycle arrest mechanisms independent of cyclin CCND1 interaction. Clinically, INSM1 serves as a valuable diagnostic biomarker for neuroendocrine neoplasms across multiple organ systems. It is highly expressed in well-differentiated neuroendocrine tumors and neuroendocrine carcinomas of the pancreas, lung, and adrenal glands, aiding pathological classification and differentiation from non-neuroendocrine malignancies 1456. In small cell lung cancer, INSM1 expression correlates with neuroendocrine-high tumors 7. Beyond neoplasia, INSM1 downregulation in beta cells accompanies dedifferentiation in type 2 diabetes pathogenesis, suggesting involvement in metabolic disease 8.